Unrelated donor transplant recipients given Thymoglobuline have superior GRFS when compared to matched related donor recipients transplanted without ATG

Allogeneic hematopoietic stem cell transplantation (HSCT) is a cornerstone of curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)1,2. However, HSCT can be associated with significant morbidity and mortality, with major complications including infection, disease relapse and graft-versus-host disease (GVHD). Chronic GVHD in particular can severely impact the quality of life of survivors3. Its importance has been recognized by the increased reporting of composite outcomes such as GVHD-free, relapse-free survival (GRFS)4.

Source: Biology of Blood and Marrow Transplantation - July 3, 2020 Category: Hematology Authors: Jad Othman, Matthew Greenwood, John Moore, Stephen Larsen, Anne-Marie Watson, Chris Arthur, Abir Bhattacharyya, Ian Bilmon, Emily Blyth, Adam Bryant, Christian Bryant, Lindsay Dunlop, Keith Fay, John Gibson, Nada Hamad, Ian Kerridge, John Kwan, David Ma, Source Type: research